(a) On a quarterly basis at a time prescribed by the department and in a format prescribed by the department, commencing no earlier than January 1, 2019, a manufacturer shall report to the department all of the following information for each drug for which an increase in wholesale acquisition cost is described in Section 127677:

1. (1) A description of the specific financial and nonfinancial factors used to make the decision to increase the wholesale acquisition cost of the drug and the amount of the increase, including, but not limited to, an explanation of how these factors explain the increase in the wholesale acquisition cost of the drug.
2. (2) A schedule of wholesale acquisition cost increases for the drug for the previous five years if the drug was manufactured by the company.

3. (3) If the drug was acquired by the manufacturer within the previous five years, all of the following information:

   1. (A) The wholesale acquisition cost of the drug at the time of acquisition and in the calendar year prior to acquisition.
   2. (B) The name of the company from which the drug was acquired, the date acquired, and the purchase price.
   3. (C) The year the drug was introduced to market and the wholesale acquisition cost of the drug at the time of introduction.
4. (4) The patent expiration date of the drug if it is under patent.
5. (5) If the drug is a multiple source drug, an innovator multiple source drug, a noninnovator multiple source drug, or a single source drug, as defined in subparagraph (A) of paragraph (7) of subdivision (k) of Section 1396r–8 of Title 42 of the United States Code.
6. (6) A description of the change or improvement in the drug, if any, that necessitates the price increase.
7. (7) Volume of sales of the manufacturer’s drug in the United States for the previous year.